Find Olaparib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 763113-22-0, Lynparza, Azd2281, Azd-2281, Ku-0059436, Azd 2281
Molecular Formula
C24H23FN4O3
Molecular Weight
434.5  g/mol
InChI Key
FDLYAMZZIXQODN-UHFFFAOYSA-N
FDA UNII
WOH1JD9AR8

Olaparib
Olaparib is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.
Olaparib is a Poly(ADP-Ribose) Polymerase Inhibitor. The mechanism of action of olaparib is as a Poly(ADP-Ribose) Polymerase Inhibitor.
1 2D Structure

Olaparib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
2.1.2 InChI
InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
2.1.3 InChI Key
FDLYAMZZIXQODN-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
2.2 Other Identifiers
2.2.1 UNII
WOH1JD9AR8
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Azd 2281

2. Azd-2281

3. Azd221

4. Azd2281

5. Lynparza

2.3.2 Depositor-Supplied Synonyms

1. 763113-22-0

2. Lynparza

3. Azd2281

4. Azd-2281

5. Ku-0059436

6. Azd 2281

7. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine

8. Olaparib (azd-2281)

9. 4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one

10. Ku-59436

11. Olaparib (azd2281, Ku-0059436)

12. 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2h-phthalazin-1-one

13. Az2281

14. Mfcd13185161

15. Woh1jd9ar8

16. Nsc-747856

17. C24h23fn4o3

18. Chebi:83766

19. 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2h)-one

20. 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one

21. Az-2281

22. Keylynk-010 Component Olaparib

23. Ku59436

24. Olaparib Component Of Keylynk-010

25. Olaparib [inn]

26. Olaparib Cpd

27. Olaparib (azd2281; Ku-0059436)

28. Olaparib [usan:inn]

29. Unii-woh1jd9ar8

30. Olaparib (azd2281)

31. Acylpiperazine Analogue, 47

32. Olaparibum

33. Azd221

34. 4-[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2h)-one

35. Olaparib- Bio-x

36. Lynparza (tn)

37. 09l

38. 4-((3-((4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl)-4-fluorophenyl)methyl)phthalazin-1(2h)-one

39. 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2h)-one

40. 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2h)-one

41. Ku 59436

42. Olaparib [usan]

43. Olaparib [jan]

44. Ku0059436

45. Olaparib [mi]

46. Olaparib [vandf]

47. Olaparib - Azd2281

48. Olaparib [mart.]

49. Olaparib [who-dd]

50. Azd-2281 (olaparib)

51. Olaparib (jan/usan/inn)

52. Mls006010185

53. Schembl426568

54. Olaparib [orange Book]

55. Chembl521686

56. Gtpl7519

57. Bdbm27566

58. Dtxsid60917988

59. Ex-a002

60. Bcpp000360

61. Hms3295i09

62. Hms3426c03

63. Hms3654g13

64. Hms3746k07

65. Hms3870h03

66. Amy10295

67. Bcp01872

68. 763113-22-0, Lynparza,

69. Nsc747856

70. Nsc753686

71. S1060

72. Zinc40430143

73. Akos005145764

74. Ac-7939

75. Bcp9000363

76. Ccg-264799

77. Cs-0075

78. Db09074

79. Ex-7210

80. Nsc 747856

81. Nsc-753686

82. Sb14617

83. Ss-4573

84. Azd2281,olaparib, Ku-0059436

85. Ncgc00238451-01

86. Ncgc00238451-02

87. Ncgc00238451-08

88. Ncgc00238451-09

89. Ncgc00238451-11

90. 4-[(3-{[4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2h)-one

91. 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2h)-phthalazinone

92. Bo164169

93. Hy-10162

94. Smr004701291

95. Sy040527

96. Olaparib(azd2281,kudosku-0059436)

97. A9666

98. Bb 0260909

99. Ft-0651458

100. Ku 0059436

101. Sw218142-2

102. Ec-000.2324

103. D09730

104. J-503540

105. Q7083106

106. Brd-k02113016-001-08-9

107. Brd-k02113016-001-09-7

108. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine

109. 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one

110. (2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-

111. 1(2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-

112. 1021843-02-6

113. 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one

114. Piperazine, 1-(cyclopropylcarbonyl)-4-(5-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)-2-fluorobenzoyl)-

2.4 Create Date
2008-02-11
3 Chemical and Physical Properties
Molecular Weight 434.5 g/mol
Molecular Formula C24H23FN4O3
XLogP31.9
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Exact Mass434.17541877 g/mol
Monoisotopic Mass434.17541877 g/mol
Topological Polar Surface Area82.1 Ų
Heavy Atom Count32
Formal Charge0
Complexity790
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of: - Ovarian cancer, in which the medication is intended for [a] the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy, or [b] for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib. - Breast cancer, in which the medication is intended for use in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib.


FDA Label


* Ovarian cancer :

Lynparza is indicated as monotherapy for the:

- maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

- maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Lynparza in combination with bevacizumab is indicated for the:

- maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5. 1).

* Breast cancer :

Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer . Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5. 1).

Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.

* Adenocarcinoma of the pancreas:

Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.

* Prostate cancer :

Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.

Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum based chemotherapy.


5 Pharmacology and Biochemistry
5.1 Pharmacology

The effect of olaparib on cardiac repolarization was assessed in 119 patients following a single dose of 300 mg and in 109 patients following multiple dosing of 300 mg twice daily. No clinically relevant effect of olaparib on QT interval was observed.


5.2 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Poly(ADP-ribose) Polymerase Inhibitors

Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. (See all compounds classified as Poly(ADP-ribose) Polymerase Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
OLAPARIB
5.3.2 FDA UNII
WOH1JD9AR8
5.3.3 Pharmacological Classes
Poly(ADP-Ribose) Polymerase Inhibitors [MoA]; Poly(ADP-Ribose) Polymerase Inhibitor [EPC]
5.4 ATC Code

L01XK01


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01X - Other antineoplastic agents

L01XK - Poly (adp-ribose) polymerase (parp) inhibitors

L01XK01 - Olaparib


5.5 Absorption, Distribution and Excretion

Absorption

Following oral administration, the absorption of olaparib is very rapid and can reach a peak concentration ranging between 4.7 and 9.1 mcg/ml after 1-3 hours. The reported AUC of olaparib after a dose of 200 mg is of 25.8 mcg.h/L and this AUC can be increased by 26% with constant administration. The consumption of a high-fat diet with olaparib can only decrease the tmax but do not have an effect in the peak concentration.


Route of Elimination

From the administered dose, approximately 86% of the administered dose is recovered after 7 days from which 44% is found in the urine and 42% is obtained in feces.


Volume of Distribution

After administration of a dose of 100 mg/kg, the reported volume of distribution was of 40.3 L.


Clearance

The total clearance of olaparib was reported to be 4.6 L/h.


5.6 Metabolism/Metabolites

Olaparib is extensively metabolized in the liver by the action of CYP3A isoenzymes. From the administered dose, the unchanged form of olaparib accounted for 70% of the circulating dose and it was considered the major component in urine and feces. The metabolic pathway of olaparib is mainly attributable to oxidation reactions with subsequent glucuronide and sulfate conjugation. However, the over 20 metabolites found in plasma, urine, and feces represented a minor portion of the administered dose. The major circulating metabolites were represented by the mono-oxygenated form and the piperazin-3-ol form.


5.7 Biological Half-Life

The reported elimination half-life ranges between 5 to 11 hours.


5.8 Mechanism of Action

Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.


USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2022-04-19

Pay. Date : 2022-03-31

DMF Number : 35742

Submission : 2021-03-30

Status : Active

Type : II

Dr Reddy Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 40467

Submission : 2024-09-28

Status : Active

Type : II

Biophore

03

APGA Annual Conference
Not Confirmed

03

APGA Annual Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-05-31

Pay. Date : 2018-02-22

DMF Number : 32505

Submission : 2018-03-28

Status : Active

Type : II

blank

04

APGA Annual Conference
Not Confirmed

04

APGA Annual Conference
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 31219

Submission : 2016-12-15

Status : Active

Type : II

blank

05

Cipla Ltd

India

USDMF

arrow
APGA Annual Conference
Not Confirmed

05

Cipla Ltd

India
arrow
APGA Annual Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-08-29

Pay. Date : 2022-08-10

DMF Number : 37240

Submission : 2022-08-01

Status : Active

Type : II

blank

06

Hetero Labs Ltd

India

USDMF

arrow
APGA Annual Conference
Not Confirmed

06

APGA Annual Conference
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 35831

Submission : 2021-04-17

Status : Active

Type : II

blank

07

APGA Annual Conference
Not Confirmed

07

APGA Annual Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-10-12

Pay. Date : 2023-08-29

DMF Number : 34698

Submission : 2020-03-31

Status : Active

Type : II

blank

08

Olon Spa

Italy

USDMF

arrow
APGA Annual Conference
Not Confirmed

08

Olon Spa

Italy
arrow
APGA Annual Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-03-21

Pay. Date : 2022-12-22

DMF Number : 37779

Submission : 2023-02-09

Status : Active

Type : II

blank

09

Scinopharm Taiwan Ltd

Taiwan

USDMF

arrow
APGA Annual Conference
Not Confirmed

09

APGA Annual Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-11-16

Pay. Date : 2018-09-27

DMF Number : 32629

Submission : 2018-04-20

Status : Active

Type : II

blank

10

APGA Annual Conference
Not Confirmed

10

APGA Annual Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-07-10

Pay. Date : 2023-06-08

DMF Number : 38395

Submission : 2023-06-18

Status : Active

Type : II

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

OLAPARIB

NDC Package Code : 71796-034

Start Marketing Date : 2021-11-01

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Dr Reddy Company Banner

02

APGA Annual Conference
Not Confirmed
arrow
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

NDC Package Code : 46708-904

Start Marketing Date : 2018-03-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (25kg/25kg)

Marketing Category : BULK INGREDIENT

blank

03

APGA Annual Conference
Not Confirmed
arrow
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

NDC Package Code : 54864-843

Start Marketing Date : 2017-08-18

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

APGA Annual Conference
Not Confirmed
arrow
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

NDC Package Code : 68554-0120

Start Marketing Date : 2014-12-19

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

Lonza AG

U.S.A
APGA Annual Conference
Not Confirmed
arrow

Lonza AG

U.S.A
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

NDC Package Code : 49187-0741

Start Marketing Date : 2018-01-19

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

Lonza AG

U.S.A
APGA Annual Conference
Not Confirmed
arrow

Lonza AG

U.S.A
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

NDC Package Code : 49187-0740

Start Marketing Date : 2011-01-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

07

APGA Annual Conference
Not Confirmed
arrow
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

NDC Package Code : 54893-0099

Start Marketing Date : 2020-03-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

Olon S.p.A.

Italy
APGA Annual Conference
Not Confirmed
arrow

Olon S.p.A.

Italy
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

NDC Package Code : 17337-0319

Start Marketing Date : 2022-12-16

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

09

APGA Annual Conference
Not Confirmed
arrow
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

NDC Package Code : 65129-1464

Start Marketing Date : 2018-05-18

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

10

APGA Annual Conference
Not Confirmed
arrow
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

NDC Package Code : 65129-1400

Start Marketing Date : 2018-05-18

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Olaparib

About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
Dr Reddy Company Banner

02

Kinsy SL

Spain
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothReliable Spanish CDMO Delivering High-Quality APIs and Intermediates with Excellence, Flexibility, and Regulatory Compliance.

Flag Spain
Digital Content Digital Content

Olaparib

About the Company : Kinsy, an independent CDMO in Spain, offers over 30 years of expertise in developing and manufacturing advanced pharmaceutical intermediates and APIs. We provide innovative route d...

Kinsy, an independent CDMO in Spain, offers over 30 years of expertise in developing and manufacturing advanced pharmaceutical intermediates and APIs. We provide innovative route development, analytical method optimization, pilot plant scale-up, and clinical-phase production with advanced purification techniques. Our services include process validation, commercial-scale manufacturing (>100 MT/year), and regulatory support (DMF, CEP, REACH). ISO 9001-certified and operating under cGMP standards audited by AEMPS, we are a trusted partner to leading global pharmaceutical companies.
Kinsy SL Company Banner

03

Axplora

Germany
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAxplora is your partner of choice for complex APIs.

Flag Germany
Digital Content Digital Content

Olaparib

About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-qual...

Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
Axplora CB

04

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Olaparib

About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.
LGM Pharma CB

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Flag U.S.A
Digital Content Digital Content

Olaparib

About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...

Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quality ingredients manufactured in China. Headquartered in the Hauppauge, New York, Rochem has 16 offices spread across the globe to cater to the needs of its customers. Rochem’s operations are fully cGMP compliant and has been audited by the USFDA as well as several multinational organizations. It also trains and audits its partners to ensure all of their technologies and systems are FDA-compliant.
Rochem

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

Flag India
Digital Content Digital Content

Olaparib

About the Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cyto...

Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cytotoxic & oncology products. It has 2 R&D centers & 3 cGMP plants successfully audited by the USFDA, EUGMP, EDQM, KFDA & COFEPRIS. It offers CDMO services for generic APIs & NCEs, intermediates & key building blocks.Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Aarti Industries Company Banner

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Flag China
Digital Content Digital Content

Olaparib

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include customized R&D as well as the production of small molecule pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for both international and domestic pharmaceutical firms. Our capabilities span from laboratory-scale kilograms to commercial ton-scale production. Additionally, we are committed to independent research and development, as well as the production and sales of high-end pharmaceutical intermediates and API products.
Jinan Tantu Chemicals

08

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Olaparib

About the Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...

​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry.
Shanghai Minbiotech CB

09

APGA Annual Conference
Not Confirmed
arrow
arrow
APGA Annual Conference
Not Confirmed

Olaparib

About the Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with...

Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with vast experience across the pharmaceutical value chain, the company is on a mission to become the most preferred partner for pharmaceuticals. At Aurore, we aim to push the boundaries to manufacture and deliver high quality products that can be relied upon by both customers and regulators. Our thrust on rapidly adding capabilities have led us to acquire, integrate and expand our reach across the geographies.
blank

10

Cdymax

India
APGA Annual Conference
Not Confirmed
arrow

Cdymax

India
arrow
APGA Annual Conference
Not Confirmed

Olaparib

About the Company : Cdymax (India) Pharma Private Limited was founded in 1994. The company's line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparat...

Cdymax (India) Pharma Private Limited was founded in 1994. The company's line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparations for human or veterinary use.CDYMAX ensures and adherence to HSE practices. System and procedures are in place to control and monitoring. All employees under go periodic health check-up once in a year and twice in a year for oncology employees. Effluent treatment plant meeting Government regulation.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642357800,"product":"OLAPARIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"12500","totalValueFC":"36902.6","currency":"USD","unitRateINR":916333.33333333337,"date":"17-Jan-2022","totalValueINR":"2749000","totalValueInUsd":"36902.6","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"7529366","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653589800,"product":"OLAPARIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"AMMAN","customer":"UNDISCLOSED","customerCountry":"JORDAN","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"9000","totalValueFC":"22177.4","currency":"USD","unitRateINR":685600,"date":"27-May-2022","totalValueINR":"1714000","totalValueInUsd":"22177.4","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"1704900","productDescription":"API","marketType":"","country":"JORDAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657132200,"product":"OLAPARIB","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"12000","totalValueFC":"3433.2","currency":"USD","unitRateINR":910000,"date":"07-Jul-2022","totalValueINR":"273000","totalValueInUsd":"3433.2","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"2676561","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB API- BATCH NO. ON0030621 AS PER","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"18667.1","currency":"USD","unitRateINR":598400,"date":"08-Sep-2022","totalValueINR":"1496000","totalValueInUsd":"18667.1","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB API- BATCH NO.ON0040721 AS PER","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"18667.1","currency":"USD","unitRateINR":598400,"date":"08-Sep-2022","totalValueINR":"1496000","totalValueInUsd":"18667.1","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB API- BATCH NO.ON0050721 AS PER","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"18667.1","currency":"USD","unitRateINR":598400,"date":"08-Sep-2022","totalValueINR":"1496000","totalValueInUsd":"18667.1","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB HOT MELT EXTRUDES- BATCH NO.024","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"2350.8","totalValueFC":"1123","currency":"USD","unitRateINR":180000,"date":"08-Sep-2022","totalValueINR":"90000","totalValueInUsd":"1123","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663525800,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"AL SAHRA TRADE PETRO DMCC","customerCountry":"UNITED ARAB EMIRATES","quantity":"2.55","actualQuantity":"2.55","unit":"KGS","unitRateFc":"14730.8","totalValueFC":"36485.7","currency":"EURO","unitRateINR":1146666.6666666667,"date":"19-Sep-2022","totalValueINR":"2924000","totalValueInUsd":"36485.7","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"4276820","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1664735400,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"AL SAHRA TRADE PETRO DMCC","customerCountry":"UNITED ARAB EMIRATES","quantity":"2.55","actualQuantity":"2.55","unit":"KGS","unitRateFc":"14730.8","totalValueFC":"35535.4","currency":"EURO","unitRateINR":1146666.6666666667,"date":"03-Oct-2022","totalValueINR":"2924000","totalValueInUsd":"35535.4","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"4602292","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669660200,"product":"OLAPARIB PLACEBO","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"2","totalValueFC":"183.8","currency":"USD","unitRateINR":150,"date":"29-Nov-2022","totalValueINR":"15000","totalValueInUsd":"183.8","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5806511","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669660200,"product":"OLAPARIB PREMIX IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"2500","totalValueFC":"27385.5","currency":"USD","unitRateINR":186250,"date":"29-Nov-2022","totalValueINR":"2235000","totalValueInUsd":"27385.5","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5806511","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675881000,"product":"OLAPARIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"10500","totalValueFC":"20377.8","currency":"USD","unitRateINR":841500,"date":"09-Feb-2023","totalValueINR":"1683000","totalValueInUsd":"20377.8","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"7668165","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1678905000,"product":"OLAPARIB API","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO LLC","customerCountry":"UNITED STATES","quantity":"21.00","actualQuantity":"21","unit":"KGA","unitRateFc":"6648.5","totalValueFC":"138769.8","currency":"USD","unitRateINR":543517.61904761905,"date":"16-Mar-2023","totalValueINR":"11413870","totalValueInUsd":"138769.8","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29337990","bill_no":"4001590","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad-ZIPL-SEZ","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1687372200,"product":"OLAPARIB, B.NO. 2304003868, MFG.DT. MAY-","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"UNDISCLOSED","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"15000","totalValueFC":"4452.8","currency":"USD","unitRateINR":1219998.78,"date":"22-Jun-2023","totalValueINR":"365999.634","totalValueInUsd":"4452.8","indian_port":"BOMBAY AIR","hs_no":"29331999","bill_no":"0","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691519400,"product":"OLAPARIB BATCH NO;OLBB022001","address":"NA","city":"BANGALORE","supplier":"ACEBRIGHT INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"LOTUS PHARMACEUTICAL CO LTD","customerCountry":"TAIWAN","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"6000","totalValueFC":"8541.9","currency":"USD","unitRateINR":471721.614,"date":"09-Aug-2023","totalValueINR":"707582.421","totalValueInUsd":"8541.9","indian_port":"BANGALORE AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"NA, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692642600,"product":"OLAPARIB IH","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,","city":"HYDERABAD,TELANGANA","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"MONTREAL","customer":"PHARMASCIENCE INC","customerCountry":"CANADA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"8428.9","totalValueFC":"16728.3","currency":"USD","unitRateINR":692855,"date":"22-Aug-2023","totalValueINR":"1385710","totalValueInUsd":"16728.3","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000523","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1693247400,"product":"OLAPARIB - BATCH NO. OLP-23001, MANUFACTURING DT.","address":"S-553 GREATER KAILASH-II","city":"NEW DELHI","supplier":"SAI PHYTOCEUTICALS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"CARPE SCHEIDER Y CIA S A","customerCountry":"ARGENTINA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"10.5","totalValueFC":"1036.1","currency":"USD","unitRateINR":858.28308000000004,"date":"29-Aug-2023","totalValueINR":"85828.308","totalValueInUsd":"1036.1","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"S-553 GREATER KAILASH-II, NEW DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702924200,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"MUSCAT","customer":"SMART SUPPLY INTERNATIONAL LLC","customerCountry":"OMAN","quantity":"0.35","actualQuantity":"0.35","unit":"KGS","unitRateFc":"8000","totalValueFC":"2967.2","currency":"EURO","unitRateINR":705714.2857142858,"date":"19-Dec-2023","totalValueINR":"247000","totalValueInUsd":"2967.2","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"6153419","productDescription":"API","marketType":"","country":"OMAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703010600,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"AMEDART LLC","customerCountry":"RUSSIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"4789.6","totalValueFC":"4749.8","currency":"USD","unitRateINR":395385,"date":"20-Dec-2023","totalValueINR":"395385","totalValueInUsd":"4749.8","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000819","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1706553000,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"BIOPROFARMA BAGO S A","customerCountry":"ARGENTINA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"21000","totalValueFC":"5993.8","currency":"USD","unitRateINR":1660516.6666666667,"date":"30-Jan-2024","totalValueINR":"498155","totalValueInUsd":"5993.8","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"7118633","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708540200,"product":"OLAPARIB BATCH NO;OLBB23003","address":"N0 116\/117, KIADB INDUSTRIAL AREA,","city":"BANGALORE","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"LOTUS PHARMACEUTICAL COLTD","customerCountry":"TAIWAN","quantity":"0.90","actualQuantity":"0.9","unit":"KGS","unitRateFc":"6000","totalValueFC":"5009.5","currency":"USD","unitRateINR":461842.2888888889,"date":"22-Feb-2024","totalValueINR":"415658.06","totalValueInUsd":"5009.5","indian_port":"Bangalore Air","hs_no":"29339990","bill_no":"7744186","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1718217000,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NAN-T OU","customer":"LOTUS PHARMACEUTICAL CO LTD","customerCountry":"TAIWAN","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"8464.3","totalValueFC":"16750.3","currency":"USD","unitRateINR":699153.5,"date":"13-Jun-2024","totalValueINR":"1398307","totalValueInUsd":"16750.3","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000447","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1723573800,"product":"OLAPARIB IH","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,","city":"HYDERABAD,TELANGANA","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NEWARK","customer":"RIA INTERNATIONAL LLC","customerCountry":"UNITED STATES","quantity":"2.95","actualQuantity":"2.95","unit":"KGS","unitRateFc":"10000","totalValueFC":"29046.6","currency":"USD","unitRateINR":825895.13898305083,"date":"14-Aug-2024","totalValueINR":"2436390.66","totalValueInUsd":"29046.6","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"3205305","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728239400,"product":"OLAPARIB 1H","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"TUTEUR SACIFIA","customerCountry":"ARGENTINA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"9000","totalValueFC":"264323.4","currency":"USD","unitRateINR":740339.33333333337,"date":"07-Oct-2024","totalValueINR":"22210180","totalValueInUsd":"264323.4","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"4642259","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731349800,"product":"ACTIVEPHARMACEUTICALSINGREDIENTS(API)EXPORT INVOICENUMBER:F32512200871DT.08.11.2024 OLAPARIB","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK LIFE SCIENCES LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO APT\/MOS","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"756641","totalValueFC":"4348.8","currency":"INR","unitRateINR":733981,"date":"12-Nov-2024","totalValueINR":"366990.5","totalValueInUsd":"4348.8","indian_port":"Dahez-SEZ","hs_no":"29334900","bill_no":"5538644","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1733077800,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"GLOBAL PROJECT CELIK SANAYU DIS TI","customerCountry":"TURKEY","quantity":"9.40","actualQuantity":"9.4","unit":"KGS","unitRateFc":"9105.9","totalValueFC":"84216.3","currency":"USD","unitRateINR":761252.08404255309,"date":"02-Dec-2024","totalValueINR":"7155769.59","totalValueInUsd":"84216.3","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"6112943","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1733164200,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"GLOBAL PROJECT CELIK SANAYU DIS TI","customerCountry":"TURKEY","quantity":"9.40","actualQuantity":"9.4","unit":"KGS","unitRateFc":"9105.9","totalValueFC":"84216.3","currency":"USD","unitRateINR":761252.08404255309,"date":"03-Dec-2024","totalValueINR":"7155769.59","totalValueInUsd":"84216.3","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"6120876","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1733423400,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS-(API)(PHARMACEUTICALS RAW MATERIAL) PRODUCT NAME-OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"MOSCOW","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"3000","totalValueFC":"1120.3","currency":"USD","unitRateINR":190385.88,"date":"06-Dec-2024","totalValueINR":"95192.94","totalValueInUsd":"1120.3","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"6237307","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734978600,"product":"ACTIVE PHARMA INGREDIENTS (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) PRODUCT NAME - OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"9500","totalValueFC":"46831.5","currency":"USD","unitRateINR":795844.54000000004,"date":"24-Dec-2024","totalValueINR":"3979222.7","totalValueInUsd":"46831.5","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"6711693","productDescription":"API","marketType":"REGULATED MARKET","country":"REPUBLIC OF KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1736361000,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO APT\/MOS","customer":"AMEDART LLC","customerCountry":"RUSSIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"4572.1","totalValueFC":"4501.7","currency":"USD","unitRateINR":388175,"date":"09-Jan-2025","totalValueINR":"388175","totalValueInUsd":"4501.7","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000007","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1747593000,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TUTEUR S A C I F I A","customerCountry":"ARGENTINA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"8075","totalValueFC":"238783.3","currency":"USD","unitRateINR":678149.65000000002,"date":"19-May-2025","totalValueINR":"20344489.5","totalValueInUsd":"238783.3","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"1955188","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1748284200,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS-(PHARMA RAW MATERIAL FOR PHARMA IND)PRODUCT-OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"UNDISCLOSED","customerCountry":"ISRAEL","quantity":"7.56","actualQuantity":"7.56","unit":"KGS","unitRateFc":"3500","totalValueFC":"25546","currency":"USD","unitRateINR":287901.68650793651,"date":"27-May-2025","totalValueINR":"2176536.75","totalValueInUsd":"25546","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"2196511","productDescription":"API","marketType":"","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1748370600,"product":"OLAPARIB (FORM-A) IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"MICROSULE ARGENTINA S.A.","customerCountry":"ARGENTINA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"9200","totalValueFC":"8991.4","currency":"USD","unitRateINR":766072,"date":"28-May-2025","totalValueINR":"766072","totalValueInUsd":"8991.4","indian_port":"Hyderabad Air","hs_no":"29334990","bill_no":"2211362","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1748889000,"product":"OLAPARIB BATCH NO:OLBD24001","address":"N0 116\/117, KIADB INDUSTRIAL AREA,","city":"BANGALORE","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"M\/S KRKA D.D NOVO MESTO","customerCountry":"SLOVENIA","quantity":"0.20","actualQuantity":"200","unit":"GMS","unitRateFc":"5.5","totalValueFC":"1012","currency":"USD","unitRateINR":434.79050000000001,"date":"03-Jun-2025","totalValueINR":"86958.1","totalValueInUsd":"1012","indian_port":"Bangalore Air","hs_no":"29335990","bill_no":"2393125","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1749493800,"product":"OLAPARIB","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"APRAMEYA PHARMACHEM FZCO","customerCountry":"UNITED ARAB EMIRATES","quantity":"21.00","actualQuantity":"21","unit":"KGS","unitRateFc":"3093.8","totalValueFC":"64307.9","currency":"USD","unitRateINR":263127.69,"date":"10-Jun-2025","totalValueINR":"5525681.49","totalValueInUsd":"64307.9","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"2583959","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669055400,"product":"OLAPARIB (TEST LIC.NO. TL\/AZ\/22\/002729) FOR R & D PURPOSE NOT FOR SALE (FOC)","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"BIO DURO SUNDIA","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"ZYDUS LIFESCIENCES LTD","customerCountry":"INDIA","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"409.1","currency":"USD","unitRateINR":"667674.6","date":"22-Nov-2022","totalValueINR":"33383.73","totalValueInUsd":"409.1","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"3422337","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705948200,"product":"LUT-65 OLAPARIB FORMA A (CAS763113-22-0 IUPAC4-(3-(4-(CYCLOPROPANECARBONYL)PIPERAZINE-1-CARBONYL)-4-FLOROPHENYL)METHY","address":"SANDOZ HOUSE","city":"MUMBAI ,MAHARASHTRA","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"MILAN - MALPENSA","customer":"SANDOZ PRIVATE LTD","customerCountry":"INDIA","quantity":"23.73","actualQuantity":"23.73","unit":"KGS","unitRateFc":"6600","totalValueFC":"158480.4","currency":"USD","unitRateINR":"555060","date":"23-Jan-2024","totalValueINR":"13171573.8","totalValueInUsd":"158480.4","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"9785375","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN - MALPENSA","supplierAddress":"STR. RIVOLTANA KM 6\/720053 RODANO MI ITSDNF ITALY","customerAddress":"SANDOZ HOUSE"}]
17-Jan-2022
10-Jun-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

The proceeds will support advancement of the company’s clinical-stage pipeline, which includes FT-7051 (pocenbrodib) is being evaluated for metastatic castration-resistant prostate cancer.


Lead Product(s): Pocenbrodib,Abiraterone Acetate,Olaparib

Therapeutic Area: Oncology Brand Name: FT-7051

Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

Sponsor: Undisclosed

Deal Size: $365.0 million Upfront Cash: Undisclosed

Deal Type: Series D Financing May 15, 2025

blank

01

Pathos

U.S.A
arrow
APGA Annual Conference
Not Confirmed

Pathos

U.S.A
arrow
APGA Annual Conference
Not Confirmed

Details : The proceeds will support advancement of the company’s clinical-stage pipeline, which includes FT-7051 (pocenbrodib) is being evaluated for metastatic castration-resistant prostate cancer.

Product Name : FT-7051

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

May 15, 2025

blank

Details:

Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of BRCA-mutated HER2-negative high-risk early breast cancer.


Lead Product(s): Olaparib

Therapeutic Area: Oncology Brand Name: Lynparza

Study Phase: Phase IIIProduct Type: Cytotoxic Drug

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 11, 2024

blank

02

AstraZeneca

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

AstraZeneca

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Details : Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of BRCA-mutated HER2-negative high-risk early breast cancer.

Product Name : Lynparza

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

December 11, 2024

blank

Details:

Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of advanced or recurrent endometrial cancer in adults.


Lead Product(s): Olaparib,Durvalumab

Therapeutic Area: Oncology Brand Name: Lynparza

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 27, 2024

blank

03

AstraZeneca

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

AstraZeneca

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Details : Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of advanced or recurrent endometrial cancer in adults.

Product Name : Lynparza

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

November 27, 2024

blank

Details:

The funds will support the clinical development of Eisbach's first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, to treat human cancers.


Lead Product(s): EIS-12656,Olaparib

Therapeutic Area: Oncology Brand Name: EIS-12656

Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

Sponsor: CPRIT

Deal Size: $4.7 million Upfront Cash: Undisclosed

Deal Type: Funding November 26, 2024

blank

04

Eisbach Bio

Denmark
arrow
APGA Annual Conference
Not Confirmed

Eisbach Bio

Denmark
arrow
APGA Annual Conference
Not Confirmed

Details : The funds will support the clinical development of Eisbach's first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, to treat human cancers.

Product Name : EIS-12656

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

November 26, 2024

blank

Details:

RP-3467 is a Polθ ATPase inhibitor, small molecule drug candidate, which is being evaluated in combination with olaparib for the treatment of advanced solid tumors.


Lead Product(s): RP-3467,Olaparib

Therapeutic Area: Oncology Brand Name: RP-3467

Study Phase: Phase IProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 14, 2024

blank

05

APGA Annual Conference
Not Confirmed
APGA Annual Conference
Not Confirmed

Details : RP-3467 is a Polθ ATPase inhibitor, small molecule drug candidate, which is being evaluated in combination with olaparib for the treatment of advanced solid tumors.

Product Name : RP-3467

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 14, 2024

blank

Details:

EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-relevant genome reorganization induced by DNA damage. This leads to ALC1 chromatin trapping and cancer cell killing.


Lead Product(s): EIS-12656,Olaparib

Therapeutic Area: Oncology Brand Name: EIS-12656

Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 16, 2024

blank

06

Eisbach Bio

Denmark
arrow
APGA Annual Conference
Not Confirmed

Eisbach Bio

Denmark
arrow
APGA Annual Conference
Not Confirmed

Details : EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-relevant genome reorganization induced by DNA damage. This leads to ALC1 chromatin trapping and cancer cell killing.

Product Name : EIS-12656

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 16, 2024

blank

Details:

Imfinzi (durvalumab) a PD-L1 inhibitor which is approved in combination with Lynparza (olaparib) for the treatment of advanced or recurrent endometrial cancer.


Lead Product(s): Durvalumab,Carboplatin,Olaparib

Therapeutic Area: Oncology Brand Name: Imfinzi

Study Phase: Approved FDFProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 17, 2024

blank

07

AstraZeneca

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

AstraZeneca

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Details : Imfinzi (durvalumab) a PD-L1 inhibitor which is approved in combination with Lynparza (olaparib) for the treatment of advanced or recurrent endometrial cancer.

Product Name : Imfinzi

Product Type : Antibody

Upfront Cash : Inapplicable

June 17, 2024

blank

Details:

TNG348 is a novel selective inhibitor of USP1 which is in phase 1/2 clinical trials as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant cancers.


Lead Product(s): TNG348,Olaparib

Therapeutic Area: Oncology Brand Name: TNG348

Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 23, 2024

blank

08

APGA Annual Conference
Not Confirmed
APGA Annual Conference
Not Confirmed

Details : TNG348 is a novel selective inhibitor of USP1 which is in phase 1/2 clinical trials as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant cancers.

Product Name : TNG348

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 23, 2024

blank

Details:

Keytruda (pembrolizumab) is being evaluated with Lynparza (olaparib), a PARP inhibitor, for metastatic nonsquamous non-small cell lung cancer.


Lead Product(s): Pembrolizumab,Olaparib,Pemetrexed

Therapeutic Area: Oncology Brand Name: Keytruda

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: AstraZeneca

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 21, 2024

blank

09

Merck & Co

U.S.A
arrow
APGA Annual Conference
Not Confirmed

Merck & Co

U.S.A
arrow
APGA Annual Conference
Not Confirmed

Details : Keytruda (pembrolizumab) is being evaluated with Lynparza (olaparib), a PARP inhibitor, for metastatic nonsquamous non-small cell lung cancer.

Product Name : Keytruda

Product Type : Antibody

Upfront Cash : Inapplicable

March 21, 2024

blank

Details:

Imfinzi (durvalumab) with platinum-based chemotherapy followed by Lynparza (olaparib), demonstrated improved outcomes in patients with mismatch repair proficient advanced endometrial cancer.


Lead Product(s): Durvalumab,Olaparib

Therapeutic Area: Oncology Brand Name: Imfinzi

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 18, 2024

blank

10

AstraZeneca

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

AstraZeneca

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Details : Imfinzi (durvalumab) with platinum-based chemotherapy followed by Lynparza (olaparib), demonstrated improved outcomes in patients with mismatch repair proficient advanced endometrial cancer.

Product Name : Imfinzi

Product Type : Antibody

Upfront Cash : Inapplicable

March 18, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

APGA Annual Conference
Not Confirmed
arrow
APGA Annual Conference
Not Confirmed
arrow

CAS Number : 57260-71-6

End Use API : Olaparib

About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

blank

02

APGA Annual Conference
Not Confirmed
arrow
APGA Annual Conference
Not Confirmed
arrow

CAS Number : 1759-53-1

End Use API : Olaparib

About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

blank

03

APGA Annual Conference
Not Confirmed
arrow
APGA Annual Conference
Not Confirmed
arrow

CAS Number : 4023-34-1

End Use API : Olaparib

About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

blank

04

APGA Annual Conference
Not Confirmed
arrow
APGA Annual Conference
Not Confirmed
arrow

CAS Number : 59878-57-8

End Use API : Olaparib

About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

blank

05

APGA Annual Conference
Not Confirmed
arrow
APGA Annual Conference
Not Confirmed
arrow

CAS Number : 218301-22-5

End Use API : Olaparib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

06

APGA Annual Conference
Not Confirmed
arrow
APGA Annual Conference
Not Confirmed
arrow

CAS Number : 763114-26-7

End Use API : Olaparib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

07

APGA Annual Conference
Not Confirmed
arrow
APGA Annual Conference
Not Confirmed
arrow

CAS Number : 61260-15-9

End Use API : Olaparib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

08

APGA Annual Conference
Not Confirmed
arrow
APGA Annual Conference
Not Confirmed
arrow

CAS Number : 4023-34-1

End Use API : Olaparib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

09

APGA Annual Conference
Not Confirmed
arrow
APGA Annual Conference
Not Confirmed
arrow

CAS Number : 59878-57-8

End Use API : Olaparib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

10

Inventys

India
APGA Annual Conference
Not Confirmed
arrow

Inventys

India
APGA Annual Conference
Not Confirmed
arrow

CAS Number : 1759-53-1

End Use API : Olaparib

About The Company : INVENTYS Research Company – India’s Leading CDMO of Actives, Advanced Intermediates, and Specialty Chemicals. A research-driven Exclusive Synthesis and CDMO...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Controlled & Modified Release

read-more
read-more

Direct Compression

read-more
read-more

Taste Masking

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Granulation

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Solubilizers

read-more
read-more

Parenteral

read-more
read-more

Empty Capsules

read-more
read-more

Coloring Agents

read-more
read-more

Topical

read-more
read-more

Vegetarian Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Emulsifying Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Company : Astrazeneca

Olaparib

Drug Cost (USD) : 487,431,793

Year : 2023

Prescribers : 5974

Prescriptions : 34461

blank

02

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Company : Astrazeneca

Olaparib

Drug Cost (USD) : 460,720,287

Year : 2022

Prescribers : 6026

Prescriptions : 34404

blank

03

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Company : Astrazeneca

Olaparib

Drug Cost (USD) : 426,649,225

Year : 2021

Prescribers : 5905

Prescriptions : 32292

blank

04

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Company : Astrazeneca

Olaparib

Drug Cost (USD) : 358,856,238

Year : 2020

Prescribers : 5337

Prescriptions : 27233

blank

05

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Company : Astrazeneca

Olaparib

Drug Cost (USD) : 242,845,094

Year : 2019

Prescribers : 3908

Prescriptions : 18317

blank

06

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Company : Astrazeneca

Olaparib

Drug Cost (USD) : 119,106,528

Year : 2018

Prescribers : 2051

Prescriptions : 9055

blank

07

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Company : Astrazeneca

Olaparib

Drug Cost (USD) : 34,328,798

Year : 2017

Prescribers : 756

Prescriptions : 3194

blank

08

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Company : Astrazeneca

Olaparib

Drug Cost (USD) : 48,125,767

Year : 2016

Prescribers : 958

Prescriptions : 4660

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Lynparza

Olaparib

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 1,776

2019 Revenue in Millions : 1,198

Growth (%) : 48

blank

02

Brand Name : Lynparza

Olaparib

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

U.S.A
arrow
APGA Annual Conference
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 725

2019 Revenue in Millions : 444

Growth (%) : 63

blank

03

Brand Name : Lynparza

Olaparib

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 2,348

2020 Revenue in Millions : 1,776

Growth (%) : 32

blank

04

Brand Name : Lynparza

Olaparib

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

U.S.A
arrow
APGA Annual Conference
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 989

2020 Revenue in Millions : 725

Growth (%) : 36

blank

05

Brand Name : Lynparza

Olaparib

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

U.S.A
arrow
APGA Annual Conference
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,116

2021 Revenue in Millions : 989

Growth (%) : 13

blank

06

Brand Name : Lynparza

Olaparib

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 2,638

2021 Revenue in Millions : 2,348

Growth (%) : 12

blank

07

Brand Name : Lynparza

Olaparib

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 2,811

2022 Revenue in Millions : 2,638

Growth (%) : 7

blank

08

Brand Name : Alliance revenue - Lynparza

Olaparib

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Alliance revenue - Lynparza

U.S.A
arrow
APGA Annual Conference
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,199

2022 Revenue in Millions : 1,116

Growth (%) : 7

blank

09

Brand Name : Alliance revenue - Lynparza

Olaparib

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Alliance revenue - Lynparza

U.S.A
arrow
APGA Annual Conference
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 1,311

2023 Revenue in Millions : 1,199

Growth (%) : 9

blank

10

Brand Name : Lynparza

Olaparib

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Lynparza

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 3,072

2023 Revenue in Millions : 2,811

Growth (%) : 9

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

US Patent Number : 8143241

Drug Substance Claim :

Drug Product Claim :

Application Number : 206162

Patent Use Code : U-1634

Delist Requested :

Patent Use Description : TREATMENT OF BRCA MUTA...

Patent Expiration Date : 2027-08-12

blank

02

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

US Patent Number : 8071579

Drug Substance Claim :

Drug Product Claim :

Application Number : 208558

Patent Use Code : U-2482

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-08-12

blank

03

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

US Patent Number : 12144810

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208558

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-10-07

blank

04

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

US Patent Number : 11633396

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208558

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-10-07

blank

05

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

US Patent Number : 8071579

Drug Substance Claim :

Drug Product Claim :

Application Number : 208558

Patent Use Code : U-2819

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-08-12

blank

06

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

US Patent Number : 8071579

Drug Substance Claim :

Drug Product Claim :

Application Number : 208558

Patent Use Code : U-2824

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-08-12

blank

07

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

US Patent Number : 8859562

Drug Substance Claim :

Drug Product Claim :

Application Number : 208558

Patent Use Code : U-2832

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-08-04

blank

08

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

US Patent Number : 8859562

Drug Substance Claim :

Drug Product Claim :

Application Number : 208558

Patent Use Code : U-2819

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-08-04

blank

09

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

US Patent Number : 8143241

Drug Substance Claim :

Drug Product Claim :

Application Number : 208558

Patent Use Code : U-3631

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-08-12

blank

10

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

US Patent Number : 8143241

Drug Substance Claim :

Drug Product Claim :

Application Number : 208558

Patent Use Code : U-2824

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-08-12

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

Exclusivity Code : I-885

Exclusivity Expiration Date : 2025-03-11

Application Number : 208558

Product Number : 1

Exclusivity Details :

blank

02

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

Exclusivity Code : I-914

Exclusivity Expiration Date : 2026-05-31

Application Number : 208558

Product Number : 1

Exclusivity Details :

blank

03

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

Exclusivity Code : ODE-226

Exclusivity Expiration Date : 2025-12-19

Application Number : 208558

Product Number : 1

Exclusivity Details :

blank

04

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

Exclusivity Code : ODE-283

Exclusivity Expiration Date : 2026-12-27

Application Number : 208558

Product Number : 1

Exclusivity Details :

blank

05

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

Exclusivity Code : ODE-306

Exclusivity Expiration Date : 2027-05-08

Application Number : 208558

Product Number : 1

Exclusivity Details :

blank

06

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

Exclusivity Code : I-885

Exclusivity Expiration Date : 2025-03-11

Application Number : 208558

Product Number : 2

Exclusivity Details :

blank

07

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

Exclusivity Code : I-914

Exclusivity Expiration Date : 2026-05-31

Application Number : 208558

Product Number : 2

Exclusivity Details :

blank

08

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

Exclusivity Code : ODE-226

Exclusivity Expiration Date : 2025-12-19

Application Number : 208558

Product Number : 2

Exclusivity Details :

blank

09

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

Exclusivity Code : ODE-283

Exclusivity Expiration Date : 2026-12-27

Application Number : 208558

Product Number : 2

Exclusivity Details :

blank

10

arrow
APGA Annual Conference
Not Confirmed

ASTRAZENECA

United Kingdom
arrow
APGA Annual Conference
Not Confirmed

OLAPARIB

Exclusivity Code : ODE-306

Exclusivity Expiration Date : 2027-05-08

Application Number : 208558

Product Number : 2

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 763113-22-0 / Olaparib API manufacturers, exporters & distributors?

Olaparib manufacturers, exporters & distributors 1

78

PharmaCompass offers a list of Olaparib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Olaparib manufacturer or Olaparib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Olaparib manufacturer or Olaparib supplier.

PharmaCompass also assists you with knowing the Olaparib API Price utilized in the formulation of products. Olaparib API Price is not always fixed or binding as the Olaparib Price is obtained through a variety of data sources. The Olaparib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Olaparib

Synonyms

763113-22-0, Lynparza, Azd2281, Azd-2281, Ku-0059436, Azd 2281

Cas Number

763113-22-0

Unique Ingredient Identifier (UNII)

WOH1JD9AR8

About Olaparib

Olaparib is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.

Olaparib Manufacturers

A Olaparib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Olaparib, including repackagers and relabelers. The FDA regulates Olaparib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Olaparib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Olaparib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Olaparib Suppliers

A Olaparib supplier is an individual or a company that provides Olaparib active pharmaceutical ingredient (API) or Olaparib finished formulations upon request. The Olaparib suppliers may include Olaparib API manufacturers, exporters, distributors and traders.

click here to find a list of Olaparib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Olaparib USDMF

A Olaparib DMF (Drug Master File) is a document detailing the whole manufacturing process of Olaparib active pharmaceutical ingredient (API) in detail. Different forms of Olaparib DMFs exist exist since differing nations have different regulations, such as Olaparib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Olaparib DMF submitted to regulatory agencies in the US is known as a USDMF. Olaparib USDMF includes data on Olaparib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Olaparib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Olaparib suppliers with USDMF on PharmaCompass.

Olaparib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Olaparib Drug Master File in Korea (Olaparib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Olaparib. The MFDS reviews the Olaparib KDMF as part of the drug registration process and uses the information provided in the Olaparib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Olaparib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Olaparib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Olaparib suppliers with KDMF on PharmaCompass.

Olaparib WC

A Olaparib written confirmation (Olaparib WC) is an official document issued by a regulatory agency to a Olaparib manufacturer, verifying that the manufacturing facility of a Olaparib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Olaparib APIs or Olaparib finished pharmaceutical products to another nation, regulatory agencies frequently require a Olaparib WC (written confirmation) as part of the regulatory process.

click here to find a list of Olaparib suppliers with Written Confirmation (WC) on PharmaCompass.

Olaparib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Olaparib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Olaparib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Olaparib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Olaparib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Olaparib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Olaparib suppliers with NDC on PharmaCompass.

Olaparib GMP

Olaparib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Olaparib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Olaparib GMP manufacturer or Olaparib GMP API supplier for your needs.

Olaparib CoA

A Olaparib CoA (Certificate of Analysis) is a formal document that attests to Olaparib's compliance with Olaparib specifications and serves as a tool for batch-level quality control.

Olaparib CoA mostly includes findings from lab analyses of a specific batch. For each Olaparib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Olaparib may be tested according to a variety of international standards, such as European Pharmacopoeia (Olaparib EP), Olaparib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Olaparib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty